Applied to Alzheimer’s disease this could suggest that genetic modifiers may suppress the impact of reduced CYFIP2 expression on amyloid production, tau hyperphosphorylation and spatial memory loss in some patients. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.